Search

everythinglearnresearchcommunity

for

Search:↓

LTBP1 is a key regulator in diseases and a potential target for new treatments.

LPA3 is crucial for embryo implantation and links LPA to prostaglandin signaling.

The protein FLCN is involved in cellular cleanup and is regulated by ULK1.

LLPS is crucial for RALF signaling, aiding plant growth and stress resilience.

Fibroblast growth factor receptor signaling controls cell development and repair, and its malfunction can cause disorders and cancer, but it also offers potential for targeted therapies.

The LTF gene may help predict and manage nonspecific orbital inflammation.

PROTAC technology shows promise for cancer treatment but needs more effective E3 ligase recruiters.

Targeting specific cell interactions may help treat skin fibrosis.

FGF9 controls which receptors it binds to through a process where two FGF9 molecules join, and changes in FGF9 can lead to incorrect receptor activation.

FLCN helps control iron levels in cells.

New LPA receptors (LPA4, LPA5, LPA6) have diverse roles in the body.

Activating liver X receptors can reduce fibrosis by stopping certain immune cells from releasing harmful proteins.

FGF signaling is a promising target for developing treatments for wounds, metabolic diseases, and cancer.

The protein folliculin, involved in a rare disease, works with another protein to control how cells stick together and their organization, and changes in this interaction can lead to disease symptoms.

GLI2 increases follistatin production in human skin cells.

Scientists successfully created and analyzed the structure of a part of the human androgen receptor with specific modulators and a peptide to understand how it binds differently in various tissues.

Mutations in the enzyme don't significantly change how it binds to its specific substances.

Baricitinib and its combination with lonafarnib improve fat cell formation in certain genetic disorders.

A new Wnt surrogate specifically targets the Frizzled7 receptor, promoting organoid formation and hair growth.

Targeting amphiregulin may improve treatment for fibrosis and cancer.

LPA 4 helps control blood and lymph vessel development in zebrafish.

Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.

Folliculin helps regulate energy and nutrient sensing, impacting Birt–Hogg–Dubé syndrome.

LGR5 mainly stays inside cells, moving to the trans-Golgi network, and this process is important for its role in cell signaling.

Targeting LPA could help treat skin disorders.

L-PGDS has specific binding sites for its functions and could help in drug delivery system design.

Targeting amphiregulin may improve treatment for fibrotic diseases and cancer.

The research developed new fortilin protein constructs for potential heart disease treatments.

Lysophospholipids can act as anti-inflammatory agents through specific receptors, but more research is needed.